In order to evaluate the efficacy of LEV in pharmacoresistant continous spikes and waves during slow sleep (CSWS) we tested its efficacy and safety in 16 children with CSWS affected by partial epilepsy of different nature (7 symptomatic, 6 cryptogenic, 3 idiopathic) at the dose of 25-50 mg/Kg/die for a period of 2 months to 3 years. Following the good results (disappearance of EEG abnormalities both at wake and during sleep in 4 cases (25%), their reduction to more than 50% in 5 (31.5%)) and the low rate of adverse events (3 drop out cases) the AA stress the possible effectiveness of LEV in children with CSWS.
Efficacy of Levetiracetam in treatment of continous spike wave during sleep (CSWS)
DARRA, Francesca;
2004-01-01
Abstract
In order to evaluate the efficacy of LEV in pharmacoresistant continous spikes and waves during slow sleep (CSWS) we tested its efficacy and safety in 16 children with CSWS affected by partial epilepsy of different nature (7 symptomatic, 6 cryptogenic, 3 idiopathic) at the dose of 25-50 mg/Kg/die for a period of 2 months to 3 years. Following the good results (disappearance of EEG abnormalities both at wake and during sleep in 4 cases (25%), their reduction to more than 50% in 5 (31.5%)) and the low rate of adverse events (3 drop out cases) the AA stress the possible effectiveness of LEV in children with CSWS.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2004 Boll LICE Darra.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Accesso ristretto
Dimensione
2.56 MB
Formato
Adobe PDF
|
2.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
